FDA Clears Cingulate to File for Marketing Approval of

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application
Advancing Discussions with Commercialization Partners...

Related Keywords

United States ,Kansas ,Kansas City ,American ,Shanej Schaffer ,Matt Kreps ,Thomas Dalton ,Ann Childress ,Darrow Associates ,Exchange Commission ,Nasdaq ,Psych Congress First Annual Poster ,Drug Administration ,American Professional Society ,Behavior Medicine Inc ,Securities Exchange ,Psych Congress ,Platform Technology ,Cingulate Inc ,Date Sufficient ,New Drug Application ,Currently Using Immediate Release Booster ,Precision Timed Release ,Attention Deficit Hyperactivity Disorder ,Cingulate Chairman ,Behavior Medicine ,Professional Society ,Related Disorders ,First Annual Poster ,Hyperactivity Disorder ,Erosion Barrier Layer ,Looking Statements ,Securities Act ,Securities Exchange Act ,Annual Report ,Public Relations ,